BioNTech acquires CureVac for $1.25bn to enhance its mRNA-based cancer treatments strategy. The deal aims to combine the strengths of both companies in mRNA technology to advance cancer immunotherapy. This acquisition follows BioNTech's focus on oncology and recent deals in the field.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing